MAP3K1
Mitogen-activated protein kinase kinase kinase 1
As of the edition of 20 October 2026, MAP3K1 (mitogen-activated protein kinase kinase kinase 1, UniProt Q13233) has 1 drug tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13233
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 1
- Disease areas
- Cancer; Nervous system; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 6
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| E-6201 | Stopped | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Eisai | Route A |
| Spirita Oncology | Route A |
The other 0 companies at MAP3K1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at MAP3K1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.